{"text": "Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> immunotherapy .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Administration of the cytokine <extra_id_0> interleukin-2 <extra_id_2> Protein <extra_id_1> ( <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> ) can result in therapeutic benefits for individuals with renal cell carcinoma and melanoma .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Here we report an analysis of the transcription factor families AP-1 , <extra_id_0> Sp1 <extra_id_2> Protein <extra_id_1> , NF-kappaB , and signal transducers and activators of transcription ( STAT ) in cancer patients ' lymphocytes before and after <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> immunotherapy , as assessed by a gel-shift assay .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "An in vitro surrogate of <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> immunotherapy is the incubation of fresh peripheral blood mononuclear cells ( PBMC ) from healthy individuals in <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> for several days , resulting in the production of lymphokine - activated killer ( LAK ) activity in these cultures .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "One purpose of this study was to describe the profile of transcription factor activation in these different populations , and assess whether the patterns observed correlated with functional differences in these cells .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Prior to in vivo <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> administration , the typical binding pattern of transcription factors in PBMC from patients resembled that seen in fresh PBMC from healthy individuals .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Over a 3-week course of <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> therapy , in most patients the binding patterns of AP-1 , <extra_id_0> Sp1 <extra_id_2> Protein <extra_id_1> , and NF-kappaB proteins changed to resemble those seen in PBMC activated by <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> in vitro .", "event": "<extra_id_0> <extra_id_0> Binding binding <extra_id_0> Theme Sp1 <extra_id_1> <extra_id_1> <extra_id_0> Positive_regulation changed <extra_id_0> Theme binding <extra_id_1> <extra_id_0> Cause IL-2 <extra_id_1> <extra_id_1> <extra_id_1>"}
{"text": "However , the cells obtained from <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> - treated patients did not have low - level constitutive expression of STAT binding factors as did LAK cells .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "When these patient cells were further stimulated by <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> in vitro , additional differences in STAT induction patterns were noted .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "These data provide further information on the molecular events occurring in immune cells generated through in vivo and in vitro administration of <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> , and further document that there is not a precise congruence between PBMC activated in vivo and in vitro by <extra_id_0> IL-2 <extra_id_2> Protein <extra_id_1> .", "event": "<extra_id_0> <extra_id_1>"}
